Table 2: Epidemiological, clinic and biological characteristics of each patients. Immunophenotypic profile

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| N° | Age (y) | Sex (M/F) | Tumoral syndrome | WBC(G/l) | Blasts % |  FAB | MPo  | Immunophenotypic profile | EGIL |
| 1 | 25 | H | Absent | 1.4 | 91 | ALL2 |  | HLA-DR+/**CD34+/**CD22+/CD20+/CD19+/**CD38-** | ALL B IV |
| 2 | 15 | F | Present | 27. 1 | 90 | ALL2 |  | CD3+/CD4+/**CD34+/**CD22+/CD20+/CD19+/**CD38-** | Biphenotypic L (B/T) |
| 3 | 66 | H | Present | 4 | 98 | ALL2 | + | CD22+/CD20+/CD19+/CD34-/CD38- | ALL B IV |
| 4 | 37 | F | Absent | 24.7 | 83 | AML2 |  | HLA-DR+/**CD34+/**CD38+ | AML  |
| 5 | 53 | F | Absent | 2  | 81 | ALL 2 | + | CD22+/CD20+/CD34-/CD38+ | ALL B IV |
| 6\* | 39 | H | Present | 4 .8 | 77 | AML4  | + | CD4+/HLA-DR+/**CD34+/CD38-** | AML  |
| 7 | 48 | H | Absent | 31.7 | 53 | AML2 |  | **CD34+/**CD22+/**CD38-** | Biphenotypic L (Myeloid/B) |
| 8 | 54 | F | Present | 47  | 61 | AL |  | CD22+/CD20+/CD19+/CD34-/CD38- | ALL B IV |
| 9 | 42 | H | Absent | 252. 6 | 42 | ALL1 |  | CD3+/CD34-/CD38+ | ALL T |
| 10 | 71 | H | Absent | 73.9 | 86 | AL |  | HLA-DR+/CD22+/CD20+/CD34-/CD38+/CD19+ | ALL B IV |
| 11 | 18 | H | Present | 109.1 | 32 | AML5 | + | HLA-DR+/**CD34+/**CD38+ | AML |
| 12 | 27 | F | Present | 5. 2 | 93 | ALL2 |  | **CD34+**/CD22+/CD20+/CD19+/**CD38-** | ALL B IV |
| 13 | 35 | H | Present | 26. 7 | 98 | ALL2 |  | HLA-DR+/**CD34+/**CD22+/CD38+ | ALL BI |
| 14 | 14 | F | Present | 2.1 | 89 | ALL2 |  | HLA-DR+/**CD34+/**CD22+/CD20+/CD19+/**CD38-** | ALL B IV |
| 15 | 05 | H | Present | 173 | 95 | ALL2 |  | HLA-DR+/**CD34+/**CD22+/**CD38-** | ALL B I |
| 16 | 51 | F | Absent | 13 | 71 | ALL1 |  | HLA-DR+/**CD34+/**CD38+ | Undifferentiated AL |
| 17 | 13 | H | Present | 1. 9 | 99 | ALL1 |  | HLA-DR+/**CD34+/**CD22+/CD20+/CD38+/CD19+ | ALL B IV |
| 18 | 09 | H | Present  | 5.7 | 96 | ALL3 |  | HLA-DR+/**CD34+/**CD22+/CD20+/CD19+/**CD38-** | ALL B IV |
| 19 | 02 | H | Absent | 15. 5 | 96 | AML5 | + | HLA-DR+/**CD34+/CD38-** | AML |
| 20 | 55 | F | Present | 79.9 | 90 | AL |  | HLA-DR+/CD22+/CD20+/CD34-/CD38+/CD19+ | ALL B IV |
| 21 | 63 | F | Absent | 89.8 | 90 | AML2 | + | HLA-DR+/**CD34+/CD38-** | AML |
| 22 | 05 | F | Present | 248  | 47 | AML5 | + | **CD34+**/CD56+/**CD38-** | AML |
| 23 | 13 | H | Present | 66  | 60 | AL | + | CD22+/CD20+/CD19+/CD34-/CD38- | AL Biclonal (Lymphoid / monoblastic) |

\*: secondary AL